Dossier assessment

Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-167
Last updated

Report documents

  1. Extract of dossier assessment

    Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 450 kB, EN, not accessible
  2. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 620 kB, DE, not accessible

Dossier assessment

Indication:

Children and adolescents aged 10 to 17 years with insufficiently controlled type 2 diabetes mellitus (T2DM), adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or in addition to other blood-glucose lowering drugs

Result of dossier assessment:
  • Insulin-naive children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing drug treatment consisting of at least one blood-glucose lowering drug in addition to diet and exercise: added benefit not proven
  • Insulin-experienced children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing insulin regimen in addition to diet and exercise: added benefit not proven

Project details

Project no.
A21-167
Commission
Commission awarded on 13.12.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-109
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-113
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-53
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-37
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A17-65
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    Project no.
    A12-18
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-11
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form